Third-Line Therapy for Advanced Non-Small-Cell Lung Cancer Patients: A Feasible Therapeutic Option?

Publisher： Karger

E-ISSN： 1423-0232|77|1|113-121

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.1, 2010-02, pp. : 113-121

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients

By  

Respiration, Vol. 82, Iss. 4, 2011-01 ,pp. : 341-350

Karger

Access to resources Recommend Favorite

Erlotinib for Metastatic Non-Small-Cell Lung Cancer: First-, Second- or Third-Line Setting – Does It Matter ?

By  

Oncology, Vol. 76, Iss. 2, 2008-12 ,pp. : 85-90

Karger

Access to resources Recommend Favorite

Hycamtin in the Therapy of Non-Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1999-01 ,pp. : 18-21

Karger

Access to resources Recommend Favorite

Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer with P-Glycoprotein Expression

By  

Respiration, Vol. 70, Iss. 1, 2003-02 ,pp. : 32-35

Karger

Access to resources Recommend Favorite

Preliminary Results of Combined Therapy with Topotecan and Carboplatin in Advanced Non-Small-Cell Lung Cancer

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 47-54

Karger

Access to resources Recommend Favorite